Pharma moves too slow.
Now it's our turn.

Accelerating a cure for Long Covid with Silicon Valley speed.

Built by scientists and engineers from Google DeepMind, UCSF, and Mayo Clinic.

The Problem

This isn't a scientific mystery. It's an infrastructure failure.

The biology is increasingly understood, but nothing is reaching patients. Data is siloed across platforms, trials aren't getting funded, and there's no diagnostic biomarker. Pharma has no economic reason to move fast on a disease it can't yet define with a blood test.

All Tasks

Waiting for approval

  • Payroll management

    Due on 2nd july

  • Employee Tracking

    2 days ago

  • Social media post

    Cancelled by user

  • Lead list

    70% prepared

  • Payment reminder

    sent to selected clients

The Problem

We acquired the largest long COVID patient dataset in existence

Millions of patients across multiple platforms. Treatments, symptoms, labs, biomarkers, and outcomes tracked longitudinally and structured for machine learning. This data existed in fragments across patient communities, EHR systems, and research cohorts. We combined it. Everything downstream starts here.

100M+ Affected

0 Approved Treatments

The Dataset

Our models rank which existing treatments actually work.

Patients are already recovering on off-label drugs, but nobody is systematically measuring which ones, for whom, or why. We run our models against the full dataset to rank therapeutics by real-world patient outcomes, stratified by symptom profile and severity. Not case reports. Not anecdotes. Signal at scale.

Longitudinal Outcomes

Largest Patient Dataset

What can I help with?

Weather you want help in customer handling or make changes in your system just give me command

|

Add document

Analyze

Generate Image

research

E-mail Sending..

LinkedIn

IT services

Founders

Draft

Schedule

Sent

Treatment Discovery

We fund clinical trials to get those treatments formally approved

A drug can work and doctors can know it works, but without an approved indication for long COVID, most physicians won't prescribe it and insurance won't cover it. We're funding trials to re-indicate the highest-signal candidates. The compounds exist. The safety data exists. What's missing is the trial funding.

Off-Label Analysis

Real-World Efficacy

Clinical Trials

We're funding the development of the first long COVID diagnostic biomarker

There is no blood test or objective measure for long COVID today. That makes trials harder to run, treatments harder to evaluate, and patients harder to believe. We're deploying capital to research institutions to build validated diagnostic biomarkers. You can't treat what you can't measure.

Trial Funding

Drug Re-indication

Hey David!

Here is your Custom project & schedule

On going project :

Customer Support Chatbot

90% Finsihed

Schedule

Mo

Tu

We

Th

Fr

Sa

Su

Discovery call

10:00 am to 10:30 am

Custom automation

06:00 pm to 06:30 pm

Our Approach

Why Now

The science exists. The patients exist. The funding doesn't

Fragmented Data

Silos kill discovery.

Misaligned Incentives

Wrong problems get funded.

No Central Coordination

Thousands of dead ends.

We raised $20M because the bottleneck was never knowledge, but capital and infrastructure. Our team spans ML, computational biology, and clinical research. We're based in San Francisco and we're moving fast